Matthew Callister - Concord Medical Chief Medical Officer
| CCM Stock | USD 5.09 0.16 3.25% |
Executive
Dr. Matthew D. Callister is Chief Medical Officer of the company. Dr. Matthew D. Callister joined Concord Medical inMarch 2019. Prior to joining Concord Medical, Dr. Callister served as the Senior Physician Executive of Banner MD Anderson Cancer Center and Service Line in 2014, the Division Chief of Radiation Oncology at Banner MD Anderson Cancer Center in 2011 and a Consultant at the Department of Radiation Oncology of Mayo Clinic Arizona in 2004. Dr. Callister was an Adjunct Associate Professor of Radiation Oncology at the UTMD Anderson Cancer Center from 2011 to present since 2019.
| Age | 50 |
| Tenure | 5 years |
| Professional Marks | Ph.D |
| Address | East Zone, Hanwei Plaza, Beijing, China, 100020 |
| Phone | 86 10 5903 6688 |
| Web | https://www.concordmedical.com |
Concord Medical Management Efficiency
The company has Return on Asset of (0.044) % which means that on every $100 spent on assets, it lost $0.044. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.324) %, meaning that it generated no profit with money invested by stockholders. Concord Medical's management efficiency ratios could be used to measure how well Concord Medical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of December 2024, Return On Equity is likely to grow to 0.27, while Return On Tangible Assets are likely to drop (0.06). At this time, Concord Medical's Other Current Assets are very stable compared to the past year. As of the 1st of December 2024, Intangible Assets is likely to grow to about 435.8 M, while Other Assets are likely to drop about 26.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| John Duggan | Select Medical Holdings | N/A | |
| Gary Delanois | American Shared Hospital | 70 | |
| Anderson Sr | National HealthCare | 62 | |
| Andrew Price | Encompass Health Corp | 57 | |
| Kirk Cheney | Pennant Group | N/A | |
| Robert Hiatt | American Shared Hospital | 58 | |
| Langham MBA | Enhabit | 47 | |
| Steven Knauf | The Joint Corp | N/A | |
| Ranjit Pradhan | American Shared Hospital | N/A | |
| FACS MD | Oncology Institute | 52 | |
| Beth Gross | The Joint Corp | N/A | |
| Greg Mercurio | American Shared Hospital | N/A | |
| Jake CPA | The Joint Corp | 42 | |
| Mary Lacey | Select Medical Holdings | N/A | |
| Jason Steik | Pennant Group | N/A | |
| Lynette CPA | Pennant Group | 46 | |
| Chad JD | The Ensign Group | 46 | |
| Christine Bent | InnovAge Holding Corp | 54 | |
| Michael Karicher | Sonida Senior Living | 54 | |
| FACHE MD | Oncology Institute | 45 | |
| Lori Habib | The Joint Corp | 44 | |
Management Performance
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.044 |
Concord Medical Services Leadership Team
Elected by the shareholders, the Concord Medical's board of directors comprises two types of representatives: Concord Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Concord. The board's role is to monitor Concord Medical's management team and ensure that shareholders' interests are well served. Concord Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Concord Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Xun Liu, Financial Controller | ||
| Zheng Cheng, President, Director and Member of Investment Committee | ||
| Qing Pan, Director | ||
| Matthew Callister, Chief Medical Officer | ||
| Fu Xiao, Chief Operating Officer | ||
| Jianyu Yang, Chairman, CEO, Chairman of Compensation Committee and Member of Investment Committee | ||
| Boxun Zhang, Independent Director | ||
| Yaw Yap, CFO and Member of Investment Committee | ||
| Ting Lee, Independent Non-Executive Director | ||
| Weibo Yin, Independent Director and Member of Audit Committee | ||
| Liping Zhang, Independent Director | ||
| Yue Yu, Director |
Concord Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Concord Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.044 | ||||
| Profit Margin | (0.80) % | ||||
| Operating Margin | (0.90) % | ||||
| Current Valuation | 468.72 M | ||||
| Shares Outstanding | 2.82 M | ||||
| Shares Owned By Insiders | 17.99 % | ||||
| Shares Owned By Institutions | 0.10 % | ||||
| Number Of Shares Shorted | 3.18 K | ||||
| Price To Earning | (3.90) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Concord Medical Services. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Concord Medical. If investors know Concord will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Concord Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.97) | Revenue Per Share 107.978 | Quarterly Revenue Growth (0.23) | Return On Assets (0.04) | Return On Equity (0.32) |
The market value of Concord Medical Services is measured differently than its book value, which is the value of Concord that is recorded on the company's balance sheet. Investors also form their own opinion of Concord Medical's value that differs from its market value or its book value, called intrinsic value, which is Concord Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Concord Medical's market value can be influenced by many factors that don't directly affect Concord Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Concord Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Concord Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Concord Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.